STAT+: A nonprofit does deals in Brazil and India to make low-cost CAR-T cell therapies widely available
STAT
MAY 8, 2024
The deals will initially involve manufacturing cell therapies for combating lymphoma and leukemia, which carry price tags in the hundreds of thousands of dollars in wealthy nations. By These are not generic versions. “But we’re not offering the same products that are approved for elsewhere.
Let's personalize your content